Should I buy or sell Glenmark Pharmaceuticals?

The average broker rating on Glenmark Pharmaceuticals is Buy. The breakup of analyst rating is given below - 0 analysts have given a strong sell rating 2 analysts have given a sell rating 6 analysts have given a hold rating 7 analysts have given a buy rating 2 analysts have given a strong buy rating

Is Glenmark Pharmaceuticals a good stock to invest in?

Glenmark Pharmaceuticals can be analyzed on the following key metrics - TTM P/E: 13.58 Sector P/E: 26.48 Dividend Yield: 0.57% D/E ratio: -

Home > Market > Market Stats > Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Share Price

Sector: Biotechnology & Drugs

426.80 -9.90 (-2.27%)

Price Range

Today’s Low 424.05

Today’s High 443.65

52 Week Low 348.9

52 Week High 487.15

Key Metrics

Market Cap (In Cr) 12323.69
Beta 1.07
Div. Yield (%) 0.57
P/B 1.36
TTM P/E 13.58
Peg Ratio 1.35
Sector P/E 26.48
D/E -
Open Price 436.8
Prev Close 436.7

View All Metrics on Mint Genie

Glenmark Pharmaceuticals Analysis

Price Analysis

1 Week

0.97%
3 Months

0.08%
6 Month

12.55%
YTD

2.97%
1 Year

-3.75%

Risk Meter

28% Low risk
28% Moderate risk
28% Balanced Risk
28% High risk
28% Extreme risk

Recos

Strong Sell
Sell
Hold
Buy
Strong Buy

Analysts' Views

Ratings
Current
1 W Ago
1 M Ago
3 M Ago

Strong Buy
2
2
2
2

Hold
6
6
6
6

Sell
2
2
2
1

Strong Sell
0
0
0
0

Total
17
17
17
17

Glenmark Pharmaceuticals Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2022

Total Revenue
12304.9

Selling/ General/ Admin Expenses Total
3374.22

Depreciation/ Amortization
486.72

Other Operating Expenses Total
1625.11

Total Operating Expense
10725.77

Operating Income
1579.14

Net Income Before Taxes
1441.25

Net Income
941.71

Diluted Normalized EPS
39.91

Period
2021

Total Revenue
10943.93

Selling/ General/ Admin Expenses Total
3242.35

Depreciation/ Amortization
443.55

Other Operating Expenses Total
1290.01

Total Operating Expense
9258.56

Operating Income
1685.37

Net Income Before Taxes
1382.48

Net Income
970.09

Diluted Normalized EPS
33.26

Period
2020

Total Revenue
10640.97

Selling/ General/ Admin Expenses Total
3254.42

Depreciation/ Amortization
417.17

Other Operating Expenses Total
1478.54

Total Operating Expense
9326

Operating Income
1314.96

Net Income Before Taxes
1096.08

Net Income
775.97

Diluted Normalized EPS
26.7

Period
2019

Total Revenue
9865.47

Selling/ General/ Admin Expenses Total
3188.08

Depreciation/ Amortization
325.91

Other Operating Expenses Total
1162.3

Total Operating Expense
8438.39

Operating Income
1427.08

Net Income Before Taxes
1300.63

Net Income
924.99

Diluted Normalized EPS
28.55

Period
2018

Total Revenue
9103.07

Selling/ General/ Admin Expenses Total
3624.5

Depreciation/ Amortization
354.07

Other Operating Expenses Total
309.1

Total Operating Expense
7842.11

Operating Income
1260.96

Net Income Before Taxes
1066.8

Net Income
774.19

Diluted Normalized EPS
27.5

Period
2017

Total Revenue
9185.68

Selling/ General/ Admin Expenses Total
3541.2

Depreciation/ Amortization
576.52

Other Operating Expenses Total
586.16

Total Operating Expense
7725.5

Operating Income
1460.18

Net Income Before Taxes
1260.15

Net Income
915.97

Diluted Normalized EPS
32.45

View detailed financials on Mint Genie

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Glenmark Pharmaceuticals Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

J B Chemicals & Pharmaceuticals
1971
1.95
0.1
2149.9
1339.05
15232.3

Sanofi India
5674.45
-6.25
-0.11
7404.27
5240
13068.61

Glenmark Pharmaceuticals
426.8
-9.9
-2.27
487.15
348.9
12042.94

Suven Pharmaceuticals
470.6
-0.8
-0.17
623.51
387.5
11979.83

Natco Pharma
537.7
-10.55
-1.92
846.7
502
9814.11

Glenmark Pharmaceuticals Shareholding

Category
Percentage
No. of shares

Public Shareholding
53.35%
150,550,469

HSBC POOLED INVESTMENT FUND - HSBC POOLED ASIA PAC
3.48%
9,827,221

ELLIPSIS PARTNERS LLC
1.68%
4,750,000

HSBC GLOBAL INVESTMENT FUNDS - ASIA EX JAPAN EQUIT
1.04%
2,948,112

Others
14.2%
40,047,086

Others
11.78%
33,235,052

HDFC LARGE AND MID CAP FUND
2.37%
6,688,650

ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C
2.27%
6,410,385

Others
0.99%
2,821,753

ASHISH DHAWAN
2.48%
7,000,540

Others
2.46%
6,936,923

LIFE INSURANCE CORPORATION OF INDIA
2.93%
8,277,813

Others
1.55%
4,365,886

NTASAIN DISCOVERY MASTER FUND
2.34%
6,600,000

Others
0.45%
1,277,304

Others
1.26%
3,544,092

Others
0.92%
2,591,938

HUF
0.35%
976,540

Clearing Members
0.05%
139,246

Trusts
0.02%
58,746

Bodies Corporate
0%
10

Others
0.37%
1,030,500

Others
0.2%
569,188

Others
0.09%
241,492

Others
0.04%
107,037

Others
0.03%
72,058

Others
0.01%
23,560

Others
0%
8,737

Others
0%
600

Promoter & Promoter Group Shareholding
46.65%
131,617,687

SALDANHA FAMILY TRUST
45.45%
128,241,936

BLANCHE ELIZABETH SALDANHA
0.39%
1,110,327

GLENN MARIO SALDANHA
0.35%
983,439

CHERYLANN MARIA PINTO
0.27%
758,485

ROBIN JOSEPH PINTO
0.18%
497,500

NEHA SALDANHA
0.01%
26,000

Shareholding Pattern

Shareholding Trend

Shareholding(%) v/s Date

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

10-Feb-23
Quarterly Results

11-Nov-22
Quarterly Results

10-Aug-22
Quarterly Results

27-May-22
Audited Results & Final Dividend

11-Feb-22
Quarterly Results

12-Nov-21
Quarterly Results

13-Aug-21
Quarterly Results

28-May-21
Audited Results & Final Dividend

12-Feb-21
Quarterly Results & Others

Meeting Date
Announced on
Purpose

16-May-22
13-Apr-22
POM

Announced on
Record Date
Ex-Dividend
Dividend Value

30-May-22
-
12-Sept-22
2.5

28-May-21
-
08-Sept-21
2.5

Company Profile

ABOUT Glenmark Pharmaceuticals

Industry Biotechnology & Drugs
ISIN INE935A01035
BSE Code 532296
NSE Code GLENMARK

Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is primarily engaged in the business of developing, manufacturing and marketing of pharmaceutical products. It focuses on manufacturing products across therapeutic areas of respiratory, dermatology and oncology. It is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments include India, North America, Europe and Rest of the world. It is focused on developing and marketing branded and generic formulations. Its products include FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral medication to treat mild to moderate COVID-19. Its Ryaltris is a fixed-dose combination nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats symptoms associated with seasonal, as well as perennial allergic rhinitis. Its Remo is a sodium-glucose transport-2 (SGLT2) inhibitor for the type 2 diabetes.

MANAGEMENT

Glenn Saldanha Executive Chairman of the Board, Chief Executive Officer, Managing Director
V. S. Mani Global Chief Financial Officer, Executive Director
Harish Kuber Compliance Officer, Company Secretary
Cherylann Pinto Executive Director - Corporate Services

GLENMARK PHARMACEUTICALS SUMMARY

Glenmark Pharmaceuticals is trading 2.27% lower at Rs 426.80 as compared to its last closing price. Glenmark Pharmaceuticals has been trading in the price range of 443.65 & 424.05. Glenmark Pharmaceuticals has given 2.97% in this year & 0.97% in the last 5 days.

Glenmark Pharmaceuticals has TTM P/E ratio 13.58 as compared to the sector P/E of 26.48. There are 17 analysts who have initiated coverage on Glenmark Pharmaceuticals. There are 2 analysts who have given it a strong buy rating & 7 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.

The company posted a net profit of 272.58 Crores in its last quarter.

Listed peers of Glenmark Pharmaceuticals include J B Chemicals & Pharmaceuticals (0.1%), Sanofi India (-0.11%), Glenmark Pharmaceuticals (-2.27%) etc.

Glenmark Pharmaceuticals has a 46.65% promoter holding & 53.35% public holding.

FAQs about Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is trading at 426.80 as on 24 Mar, 2023 3:29:50 PM. This is -2.27% lower as compared to its previous closing price of 436.7

The market capitalization of Glenmark Pharmaceuticals is 12323.69 Cr as on 24 Mar, 2023 3:29:50 PM.

The average broker rating on Glenmark Pharmaceuticals is Buy. The breakup of analyst rating is given below -

0 analysts have given a strong sell rating
2 analysts have given a sell rating
6 analysts have given a hold rating
7 analysts have given a buy rating
2 analysts have given a strong buy rating

The 52 wk high for Glenmark Pharmaceuticals is 487.15 whereas the 52 wk low is 348.9

Glenmark Pharmaceuticals can be analyzed on the following key metrics -

TTM P/E: 13.58
Sector P/E: 26.48
Dividend Yield: 0.57%
D/E ratio: -

Glenmark Pharmaceuticals reported a net profit of 941.71 Cr in 2022.

Glenmark Pharmaceuticals Share Price

Price Range